[MCQ] Chronic hepatitis- Part 2

I. Start the exam by click the “Start” button

Chronic hepatitis- Part 2

Please wait while the activity loads.
If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled.

If loading fails, click here to try again

Start

Congratulations - you have completed Chronic hepatitis- Part 2. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rated as %%RATING%%

Your answers are highlighted below.

Question 1

Liver biopsy findings are normal or nonspecific in which of the following phase of HBV infection ?

A	Immune tolerance phase
B	Immune clearance phase
C	Inactive carrier phase
D	Reactivation phase

Question 1 Explanation:

Liver biopsy shows findings of chronic hepatitis in immune clearance and reactivation phase. Nonsignificant hepatitis is observed in inactive carrier phase.

Question 2

e antibody is positive in which of the following phase of HBV infection ?

A	Immune tolerance phase
B	Immune clearance phase
C	Inactive carrier phase
D	All of the above

Question 2 Explanation:

e antibody is negative in immune tolerance and immune clearance phase

Question 3

HBV DNA is high in which of the following phase of HBV infection ?

A	Immune tolerance phase
B	Immune clearance phase
C	Inactive carrier phase
D	Reactivation phase

Question 4

Inactive HBV carriers with a low risk of clinical progression are those with a serum HBV DNA level below ?

A	1000 IU per milliliter
B	5000 IU per milliliter
C	10000 IU per milliliter
D	10000 IU per milliliter

Question 5

Which of the following drug is beneficial in severe acute hepatitis B ?

A	Lamivudine
B	Interferon monotherapy
C	Ribavirin
D	Glucocorticoid

Question 5 Explanation:

In severe acute hepatitis B, lamivudine has been successful, although it is not an approved indication for lamivudine therapy

Question 6

Which of the following is approved for treatment of chronic HBV infection ?

A	PEG IFN
B	Adefovir
C	Entecavir
D	All of the above

Question 6 Explanation:

To date, seven drugs have been approved for treatment of chronic hepatitis B: PEG IFN, lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir.

Question 7

Which of the following drugs was the first to be approved for treatment of chronic HBV infection ?

A	Interferon α
B	Lamivudine
C	Adefovir
D	Entecavir

Question 7 Explanation:

IFN- was the first approved therapy for chronic hepatitis B.

Question 8

IFN-a therapy is not effective in which of the following groups of CHB patients ?

A	Very young children infected at birth
B	Immunosuppressed persons
C	Immunosuppressed persons
D	All of the above

Question 8 Explanation:

IFN therapy has not been effective in very young children infected at birth, in immunosuppressed persons, Asian patients with minimal-to-mild ALT elevations, or patients with decompensated chronic hepatitis B.

Question 9

Which of the following side effects of IFN- therapy is not reversible upon dose lowering or cessation of therapy ?

A	Autoimmune thyroiditis
B	Bone marrow suppression
C	Alopecia
D	Numbness & tingling of extremities

Question 9 Explanation:

Except autoimmune thyroiditis, all side effects are reversible upon dose lowering or cessation of IFN- therapy.

Question 10

Which of the following is not a ‘Nucleoside analogue’ ?

A	Lamivudine
B	Adefovir
C	Entecavir
D	Emtricitabine

Question 10 Explanation:

Adefovir dipivoxil and Tenofovir are nucleotide analogues. Lamivudine - nucleoside analogue, Entecavir - guanosine analogue polymerase inhibitor, Telbivudine - cytosine analogue, Emtricitabine - fluorinated cytosine analogue, Clevudine - pyrimidine nucleoside analogue.

Question 11

Which of the following statements about lamivudine is false ?

A	Anti-HIV & anti-HBV activity
B	Dose lower for blocking HIV replication than HBV replication
C	Not be used as monotherapy in HBV/HIV co-infected patients
D	Anti-HBe seroconversion occurs in minority of patients

Question 12

The inhibitory dose of Lamivudine for treating HBV/HIV co infected patients is ?

A	100 mg/day
B	200 mg/day
C	300 mg/day
D	400 mg/day

Question 12 Explanation:

The inhibitory dose of Lamivudine for blocking HBV replication is 100 mg/day. 300 mg/day should be given when treating HBV/HIV co-infected patients, and should always be combined with at least two other anti-HIV agents

Question 13

Long-term monotherapy with lamivudine is associated with mutation in which motif of HBV DNA polymerase ?

A	Chemokine (C-C motif) receptor 6
B	RNA-binding motif (RBM)
C	YMDD
D	YMDD

Question 13 Explanation:

Long-term monotherapy with lamivudine is associated with methionine-to-valine (M204V) or methionineto- isoleucine (M204I) mutations, primarily at amino acid 204 in the tyrosine-methionine-aspartateaspartate (YMDD) motif of HBV DNA polymerase.

Question 14

Which of the following antiviral drugs has dual antiviral activity against HBV & HIV ?

A	Enfuvirtide
B	Emtricitabine
C	Adefovir
D	Entecavir

Question 15

Which of the following antiviral drugs has dual antiviral activity against HBV & HIV ?

A	Tenofovir
B	Emtricitabine
C	Lamivudine
D	All of the above

Question 15 Explanation:

Besides lamivudine, tenofovir and emtricitabine have antiviral activity against HBV & HIV

Question 16

Which of the following is false for HBV treatment in HIV positive patient ?

A	Response to Interferon  is lower
B	Indefinite treatment with nucleoside/nucleotide analogues
C	Co-infection with hepatitis C rare
D	Frequent “Flares” while on HAART

Question 17

Which of the following has the highest rates of co-infection with HBV & HIV ?

A	Men who have sex with men
B	Intravenous drug users
C	Infection through heterosexual contacts
D	Blood transfusion

Question 18

Markers of successful anti HBV therapy include ?

A	Loss of HBeAg
B	Seroconversion to anti-HBe antibodies
C	Reduction of circulating viral load
D	All of the above

Question 19

In CHB, factor that is not predictive of a response to antiviral therapy is ?

A	Low ALT level
B	Low HBV DNA level
C	Mild-to-moderate histologic activity and stage
D	HBV genotype A>B>C>D

Question 19 Explanation:

HBV genotype A>B>C>D

Question 20

For HBeAg-reactive chronic HBV infection, antiviral therapy is indicated for patients with ?

A	ALT level more than two times upper limit of normal
B	HBV DNA > 20,000 IU per milliliter
C	Risk factors for progression
D	All of the above

Question 20 Explanation:

For HBeAg-reactive chronic HBV, antiviral therapy is indicated if ALT levels are more than twice the upper limit of normal and HBV DNA >20,000 IU/mL. Risk factors for progression (older than 40 years, family history of HCC, or ALT level in high normal range (up to twice the upper limit of normal).

Question 21

For HBeAg-negative chronic HBV infection, antiviral therapy is indicated for patients with ?

A	ALT level more than two times upper limit of normal
B	HBV DNA > 20,000 IU per milliliter
C	Moderate-to-severe necroinflammatory activity or fibrosis
D	All of the above

Question 21 Explanation:

For HBeAg-negative chronic HBV, antiviral therapy is indicated if ALT levels are more than twice the upper limit of normal and HBV DNA >20,000 IU/mL. If ALT is <2X with HBV DNA >20,000 IU/mL, liver biopsy is indicated. Moderate-to-severe necroinflammatory activity or fibrosis favours antiviral therapy

Question 22

Conversion factor for HBV DNA between international units (IU) per milliliter and copies per milliliter is about ?

A	2.6
B	3.6
C	4.6
D	5.6

Question 22 Explanation:

Conversion factor HBV DNA between international units /mL & copies/mL is ~ 5.6 (1 IU/mL is ~ 5.6 copies/mL). Treatment thresholds in copies/mL are 5 times higher than international units/mL

Question 23

Nephrotoxicity of adefovir is best related to ?

A	Acute glomerulonephritis
B	Goodpasteur's syndrome
C	Fanconi-like syndrome
D	All of the above

Question 23 Explanation:

Adefovir at 30mg has higher antiviral potency. It’s potential nephrotoxicity manifests as a Fanconilike syndrome with phosphaturia and proteinuria

Once you are finished, click the button below. Any items you have not completed will be marked incorrect. Get Results

There are 23 questions to complete.

←

List

→

Return

Shaded items are complete.

1	2	3	4	5
6	7	8	9	10
11	12	13	14	15
16	17	18	19	20
21	22	23	End

Return

See all quizzes of Chronic hepatitis at here:

Chronic hepatitis- Part 1| Chronic hepatitis- Part 2| Chronic hepatitis- Part 3| Chronic hepatitis- Part 4

1.Liver biopsy findings are normal or nonspecific in which of
the following phase of HBV infection ?
A. Immune tolerance phase
B. Immune clearance phase
C. Inactive carrier phase
D. Reactivation phase

2. e antibody is positive in which of the following phase of HBV
infection ?
A. Immune tolerance phase
B. Immune clearance phase
C. Inactive carrier phase
D. All of the above

3. HBV DNA is high in which of the following phase of HBV
infection ?
A. Immune tolerance phase
B. Immune clearance phase
C. Inactive carrier phase
D. Reactivation phase
4.Inactive HBV carriers with a low risk of clinical progression are
those with a serum HBV DNA level below ?
A. 1000 IU per milliliter
B. 5000 IU per milliliter
C. 10000 IU per milliliter
D. 10000 IU per milliliter

5. Which of the following drug is beneficial in severe acute
hepatitis B ?
A. Lamivudine
B. Interferon monotherapy
C. Ribavirin
D. Glucocorticoid

6.Which of the following is approved for treatment of chronic
HBV infection ?
A. PEG IFN
B. Adefovir
C. Entecavir
D. All of the above

7. Which of the following drugs was the first to be approved for
treatment of chronic HBV infection ?
A. Interferon 
B. Lamivudine
C. Adefovir
D. Entecavir

8. IFN-a therapy is not effective in which of the following groups
of CHB patients ?
A. Very young children infected at birth
B. Immunosuppressed persons
C. Decompensated chronic hepatitis B
D. All of the above

9.Which of the following side effects of IFN- therapy is not
reversible upon dose lowering or cessation of therapy ?
A. Autoimmune thyroiditis
B. Bone marrow suppression
C. Alopecia
D. Numbness & tingling of extremities

10.Which of the following is not a ‘Nucleoside analogue’ ?
A. Lamivudine
B. Adefovir

C. Entecavir
D. Emtricitabine

11. Which of the following statements about lamivudine is false ?
A. Anti-HIV & anti-HBV activity
B. Dose lower for blocking HIV replication than HBV replication
C. Not be used as monotherapy in HBV/HIV co-infected patients
D. Anti-HBe seroconversion occurs in minority of patients
12. The inhibitory dose of Lamivudine for treating HBV/HIV co
infected patients is ?
A. 100 mg/day
B. 200 mg/day
C. 300 mg/day
D. 400 mg/day

13.Long-term monotherapy with lamivudine is associated with
mutation in which motif of HBV DNA polymerase ?
A. Chemokine (C-C motif) receptor 6
B. RNA-binding motif (RBM)
C. YMDD
D. All of the above

14.Which of the following antiviral drugs has dual antiviral activity
against HBV & HIV ?
A. Enfuvirtide
B. Emtricitabine
C. Adefovir
D. Entecavir
15. Which of the following antiviral drugs has dual antiviral activity
against HBV & HIV ?
A. Tenofovir
B. Emtricitabine
C. Lamivudine
D. All of the above

16.Which of the following is false for HBV treatment in HIV positive
patient ?
A. Response to Interferon  is lower
B. Indefinite treatment with nucleoside/nucleotide analogues

C. Co-infection with hepatitis C rare
D. Frequent “Flares” while on HAART
17. Which of the following has the highest rates of co-infection
with HBV & HIV ?
A. Men who have sex with men
B. Intravenous drug users
C. Infection through heterosexual contacts
D. Blood transfusion
18. Markers of successful anti HBV therapy include ?
A. Loss of HBeAg
B. Seroconversion to anti-HBe antibodies
C. Reduction of circulating viral load
D. All of the above
19. In CHB, factor that is not predictive of a response to antiviral
therapy is ?
A. Low ALT level
B. Low HBV DNA level
C. Mild-to-moderate histologic activity and stage
D. HBV genotype A>B>C>D

20., For HBeAg-reactive chronic HBV infection, antiviral therapy is
indicated for patients with ?
A. ALT level more than two times upper limit of normal
B. HBV DNA > 20,000 IU per milliliter
C. Risk factors for progression
D. All of the above

21. For HBeAg-negative chronic HBV infection, antiviral therapy
is indicated for patients with ?
A. ALT level more than two times upper limit of normal
B. HBV DNA > 20,000 IU per milliliter
C. Moderate-to-severe necroinflammatory activity or fibrosis
D. All of the above

22.Conversion factor for HBV DNA between international units
(IU) per milliliter and copies per milliliter is about ?
A. 2.6
B. 3.6
C. 4.6

D. 5.6

23. Nephrotoxicity of adefovir is best related to ?
A. Acute glomerulonephritis
B. Goodpasteur’s syndrome
C. Fanconi-like syndrome
D. All of the above

Chronic hepatitis

[MCQ] Chronic hepatitis- Part 2

I. Start the exam by click the “Start” button

Chronic hepatitis- Part 2

Share this:

Related

[MCQ] Chronic hepatitis- Part 1

[MCQ] Chronic hepatitis- Part 3

You may also like

Leave a Comment Cancel Reply